Valvular & structural heart diseaseCohort study
Clinical Outcomes of a Dedicated TAVR Device for Native Aortic Regurgitation: Insights From a Multicenter Real-World Experience
- multicenter retrospective analysis
- 8 European centers
- outcomes defined per VARC-3
Authors' conclusion
In this large analysis, transfemoral transcatheter aortic valve replacement with the Trilogy valve demonstrated high procedural success and favorable hemodynamic valve performance. These findings are encouraging and suggest a potential role for the Trilogy valve in patients with symptomatic aortic regurgitation who are unsuitable for surgery.
Study context
- Population
- Patients with symptomatic aortic regurgitation who underwent transfemoral TAVR with the JenaValve Trilogy valve between June 2021 and June 2025patients included
- Participants
- 363 patients
Main finding
As reported in the abstract
Transfemoral access
Trilogy
99%
359 of 363
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Technical success | Trilogy 98% |
| Valve embolization | Trilogy 5 events · of the 5, managed with a second valve 2 · of the 5, managed surgically 2 · of the 5, required valve-in-valve reintervention 1 |
| None or trace leakage · discharge | Trilogy 86% |
| Transvalvular gradient · discharge | Trilogy mean 4 mm Hg |
| New York Heart Association class I or II · 30 days | Trilogy 88% |
| All-cause mortality (Kaplan-Meier estimated) · 6 months, 1, 2, and 3 years · among patients with available follow-up | Trilogy 6 months 4.1% · 1 year 7.0% · 2 years 15.8% · 3 years 25.9% |
Additional technical failures
- Two additional technical failures involved hemodynamic instability and a vascular complication
- Two
Safety
| Outcome | Values |
|---|---|
| Permanent pacemaker implantation | Trilogy 22% |
| In-hospital mortality | Trilogy 0.3% |
Original publication
Clinical Outcomes of a Dedicated TAVR Device for Native Aortic Regurgitation: Insights From a Multicenter Real-World Experience. Circ Cardiovasc Interv. Published 10 September 2026. doi:10.1161/circinterventions.126.016851
Summarised from the published abstract; every number is checked against it